Fasenra met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)

PUBLISHED 11 September 2023 First head-to-head trial of biologics in EGPA, comparing a single monthly injection of Fasenra to three injections per month of mepolizumab Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s Fasenra (benralizumab) met the primary endpoint of the trial and demonstrated non-inferior rates of remission compared…...

Read more

Mom Climbs Highest Mountain in Africa in Memory of Her Extraordinary Daughter

Update: Jo has made it to the top of Mt. Kilimanjaro! The climb was by far the hardest thing she’s ever had to face other than losing her daughter, Amy, to vasculitis. “They call it ‘The Roof of Africa’ but I call it almost to heaven! It’s the closest I’ll…...

Read more

VF Board of Directors Welcomes Nona Bear

Nona is a nationally known advocate of healthcare reform and champion of seniors’ issues. Originally an academic who served on the faculties of several Washington-area universities including American, Howard, and George Mason, she was hired to establish a continuing education program at the U.S. Soldiers’ and Airmen’s Home, a facility…...

Read more

New Kawasaki Disease Guideline Released by American College of Rheumatology and Vasculitis Foundation

Newswise — ATLANTA — The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released a new guideline for the management of Kawasaki disease that addresses diagnostic issues relating to Kawasaki disease, the treatment of high-risk patients, and the management of convalescent patients. Kawasaki disease is a vasculitis that…...

Read more